Denise Myshko

Researchers at Yale School of Medicine have determined that a panel of biomarkers can help physicians better understand kidney disease in children.

More than 99% effective at preventing HIV in trials, Yeztugo (lenacapavir) is now the first and only twice-yearly option for pre-exposure prophylaxis (PrEP).

Wyost and Jubbonti are interchangeable with Xgeva/Prolia and are approved for all of the same indications in bone cancer and osteoporosis.

A second patient with Duchenne muscular dystrophy has died from acute liver failure after receiving the gene therapy Elevidys.

In an interview, James D. Chambers, Ph.D., from Tufts Medical Center, talks about the factors that are impacting the biosimilar market.

GLP-1 drugs such as Ozempic and Mounjaro outperformed metformin, statins and insulin in lowering rates of age-related macular degeneration and primary open-angle glaucoma.

A cloud-based digital twin simulation, coupled with automated insulin delivery, allows patients with diabetes to experiment with their own data on glycemic control in a safe simulation environment before adjusting their system.

Patrick Roberts, Pharm.D., said his career changed when he listened to a mentor encouraging him to go back to school.

A survey by PSG has found that the pressure to control drug costs is leading some payers to look into unbundling pharmacy benefits as a way for better control.

Switching to Humira biosimilars saved Navitus clients more than $315 million in upfront costs in 2024 and resulted in a 60% reduction in net costs per claim.

Justin Jasniewski, MBA, shared a story about his career turning point and how it involved a rejected proposal and a Big Three PBM seven-figure check.

Bonnie Hui-Callahan, Pharm.D., says her career took off after not matching for a pharmacy residency—a setback that taught her resilience and led her to a better fit the second time around.

The pharmacy benefit manager (PBM) industry is under pressure to shift to models that avoid conflicts of interest and misaligned incentives.

The findings of a new study lend support for type 1 diabetes autoantibody screening in people with other autoimmune conditions to prevent complications such as diabetic ketoacidosis.

The risk of major cardiac events was 50% higher in adult-onset type 1 diabetes than in population controls, and the risk of death from diabetic coma or ketoacidosis was seven times as high as those with type 2 diabetes.

State efforts are aiming to bring more disclosure and transparency to PBM practices, mandating certain pharmacy reimbursement levels, requiring 100% pass-through rebates, and prohibiting spread pricing.

Pharmacy costs and outpatient facility care generate 69% of the cost increase for 2025, according to Milliman’s recent Medical Index.

Jason R. Smith, Pharm.D., appointed as chief pharmacy officer in February 2025 for the University of Rochester Medical Center, talks about building a stronger workforce, managing drug shortages and keeping up with changes in regulations because of the new administration.

Sibeprenlimab would be offered in a prefilled syringe for subcutaneous injection. The PDUFA target action date is Nov. 28, 2025.

Scientists working at the NIH’s BRAIN Initiative have created new viral vectors that one day could lead to gene therapies for ALS, seizure disorders, Parkinson’s and Alzheimer’s disease, Huntington’s disease and other diseases of the brain.

Nucula’s new indication is as an add-on therapy for patients with COPD who also have an elevated blood eosinophil count.

Susvimo is also approved to treat diabetic macular edema and age-related macular degeneration, and the medication, ranibizumab, is delivered through an ocular implant that is refilled every nine months.

Health plan sponsors are also expected to see a reduction in the net cost per prescription of GLP-1 medications to treat obesity.

A case analysis provides a new understanding of the ocular side effects of Blenrep, an antibody drug conjugate that is being reviewed by the FDA as a combination treatment for patients with multiple myeloma. The goal date is July 23, 2025.

Bayer’s Jivi is a factor VIII replacement therapy that has been engineered with a compound that allows for less frequent dosing. It is now indicated for patients 7 years of age and older.

A new law in Iowa, if signed by the governor, will mandate 100% pass-through of rebates, increased financial transparency, and a minimal payment for pharmacies. Critics say it will be the most costly mandate in the state’s history.

During a hearing, senators asked HHS Secretary Robert F. Kennedy Jr. to explain the rationale for the reorganization changes the agency has made since he was confirmed.

Researchers have found that Sotyktu, which inhibits the protein TYK2, protects insulin-producing beta cells and, at the same time, is able to reduce inflammation.

Industry leaders and policy experts have said President Trump’s executive order on Most Favored Drug Pricing is flawed and ignores the basic economics of the global drug marketplace.

In a press conference, President Donald J. Trump announced that he would sign an executive order that ties drug pricing to prices in other developed countries. He also vowed to cut out the “middlemen” to bring the new prices to American citizens.